Research Article
Revealing Synergistic Mechanism of Multiple Components in Gandi Capsule for Diabetic Nephropathy Therapeutics by Network Pharmacology
Table 2
Information and results of the target protein in the validity assay.
| | Number | Full name of protein | Short name of protein | Respective molecule | Test method | Results of experiment | | (μM) | max (RU) | Offset (RU) | (RU2) |
| | Acetyl-CoA carboxylase 1 | ACC1 | Astragaloside IV | SPR | 92.5 | 7.856 | 0.2424 | 0.0243 | | Morroniside | SPR | 13.63 | 2.204 | −0.2651 | 0.0962 |
| | 2 | Cyclooxygenase-2 | COX2 | Astragaloside IV | SPR | | | | | | Morroniside | SPR | 44.67 | 39.54 | 0.6314 | 0.799 | | Wogonin | SPR | | | | |
| | Superoxide dismutase [Mn] | SOD2 | Morroniside | SPR | | | | | | Wogonin | SPR | 5.08 | 14.3 | −3.611 | 2.11 |
| | | | | | | IC50 (μM) |
| | Protein kinase C, beta type | PKC-B | Morroniside | EMSA | >10000 |
| | Rho-associated protein kinase 1 | ROCK1 | Morroniside | EMSA | >10000 |
| | 6 | Mammalian target of rapamycin | mTOR | Astragaloside IV | Lance ultra | >10000 |
|
|
